

## LITERATURA

1. Vital Signs: Preventing 1 Million Heart Attacks and Strokes. [cit. 2023-02-17]. Available from <<https://www.cdc.gov/vitalsigns/million-hearts/index.html>>.
2. Dalia A. Therapeutic inertia in the management of hypertension in primary care. *J Hypertens*. 2021;39(6):1238-1245.
3. Václavík J. Kombinační léčba jednou tabletou – budoucnost léčby hypertenze? *Interní Med*. 2014;16(6):228-230.
4. Widimský J, et al. Doporučení ČSH 2022. *Hypertenze a KV prevence*. 2022;12:1-25.
5. Widimský J, jr. Trojkombinace v léčbě hypertenze. *Kardiol Rev Int Med*. 2014;16(6):449-453.
6. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39(33):3021-3104.
7. Gupta A, et al. Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-Legacy. *J Hypertens*. 2021;39 (e-Supplement 1).
8. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. *Am Heart J*. 2010;159(5):795-802.
9. Ceconi C, Fox KM, Remme WJ, et al. ACE inhibition with perindopril and endothelial dysfunction. Results of a substudy of the EUROPA study; PERTINENT. *Cardiovasc Res*. 2007;73:237-246.
10. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. *Expert rev. Cardiovasc Ther*. 2005;3:15-29.
11. Kulkarni S., Graggaber J. How to improve compliance to hypertension treatment. *E-Journal of Cardiology Practice*. 2022;22:6-23.
12. Koval S, et al. Efficacy of fixed dose of triple combination of perindopril-indapamide-amlodipine in obese patients with moderate-to-severe arterial hypertension: an open-label 6-month study. *Biomed Res Ther*. 2019;6(11):3501-3512.
13. Telejko E, et al. Perindopril arginine: benefits of a new salt of the ACE inhibitor perindopril. *Curr Med Res Opin*. 2007;23:953-960.
14. Študentová K. Triplixam v ordinaci praktického lékaře. *Med. Praxi*. 2015;12(5):261-262.
15. Snyman JR, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. *J Hypertens*. 2024;42(1):136-142.
16. Gupta P, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. *Hypertension*. 2017;70:1042-1048.
17. Visseren FLJ, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J*. 2021;42(34):3227-3337.



20.

interní medicína pro praxi

6.-7. 3. 2025  
OLOMOUC



SAVE THE DATE

Průběžně aktualizovaný program a registrace:  
[www.kongresinterna.cz](http://www.kongresinterna.cz)

PŘIPRAVOVANÉ TEMATICKÉ BLOKY:

- Komplikace imunoterapie u onkologického pacienta
- Racionální ATB terapie
- Alergologie
- Case Based Learning
- Blok ambulantních internistů
- Kardiovaskulární onemocnění
- Perspektivy medicíny

MÍSTO KONÁNÍ: **CLARION CONGRESS HOTEL OLOMOUC**  
Jeremenkova 36

